Correlation of histologic grade with other clinicopathological parameters, intrinsic subtype, and patients' clinical outcome in Taiwanese women

Japanese Journal of Clinical Oncology

Volumn 41, Issue 12, 2011, Pages 1327-1335

  Chen, Shou Tung ^a   Lai, Hung Wen ^a,b   Tseng, Hsin Shun ^a   Chen, Li Sheng ^c,d   Kuo, Shou Jen ^a,e   Chen, Dar Ren ^a,e  

^a CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Breast cancer; Estrogen receptor; HER 2; Histologic grade; Progesterone receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER SURVIVAL; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NOTTINGHAM MODIFIED BLOOM RICHARDSON GRADING SYSTEM; OUTCOME ASSESSMENT; PROGNOSIS; SCORING SYSTEM; TAIWAN; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME;

ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TAIWAN;

EID: 82955240725     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr157     Document Type: Article

References (42)

1. Lundin J, Lundin M, Holli K, Kataja V, Elomaa L, Pylkkanen L, et al. Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study. J Clin Oncol 2001;19:28-36.
2. Pereira H, Pinder SE, Sibbering DM, Galea MH, Elston CW, Blamey RW, et al. Pathological prognostic factors in breast cancer. IV: should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology 1995;27:219-26.
3. Simpson JF, Page DL. Status of breast cancer prognostication based on histopathologic data. Am J Clin Pathol 1994;102(Suppl 1):S3-8.
4. Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ, Hodi Z, et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 2008;26:3153-8.
5. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957;11:359-77.
6. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
7. Greenough RB. Varying degrees of malignancy in cancer of the breast. J Cancer Res 1925;9:452-63.
8. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:966-78.
9. Tavassoéli FA, Devilee P. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. World Health Organization Classification of Tumours. 3rd edn. Lyon: IARC Press, 2003.
10. Ellis IO, NHS Cancer Screening Programmes & Royal College of Pathologists. Pathology Reporting of Breast Disease: A Joint Document Incorporating the Third Edition of the NHS Breast Screening Programme's Guidelines for Pathology Reporting in Breast Cancer Screening and the Second Edition of the Royal College of Pathologists' Minimum Dataset for Breast Cancer Histopathology. 2nd edn. Sheffield: NHS Cancer Screening Programmes & The Royal College of Pathologists, 2005.
11. de Wolf CJM, Perry NM. European Guidelines for Quality Assurance in Mammography Screening. 2nd edn. Luxembourg: Office for Official Publications of the European Communities, 1996.
12. Davis BW, Gelber RD, Goldhirsch A, Hartmann WH, Locher GW, Reed R, et al. Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer 1986;58:2662-70.
13. Contesso G, Mouriesse H, Friedman S, Genin J, Sarrazin D, Rouesse J. The importance of histologic grade in long-term prognosis of breast cancer: a study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy. J Clin Oncol 1987;5:1378-86.
14. Schumacher M, Schmoor C, Sauerbrei W, Schauer A, Ummenhofer L, Gatzemeier W, et al. The prognostic effect of histological tumor grade in node-negative breast cancer patients. Breast Cancer Res Treat 1993;25:235-45.
15. Dalton LW, Pinder SE, Elston CE, Ellis IO, Page DL, Dupont WD, et al. Histologic grading of breast cancer: linkage of patient outcome with level of pathologist agreement. Mod Pathol 2000;13:730-5.
16. Page DL, Gray R, Allred DC, Dressler LG, Hatfield AK, Martino S, et al. Prediction of node-negative breast cancer outcome by histologic grading and S-phase analysis by flow cytometry: an Eastern Cooperative Oncology Group Study (2192). Am J Clin Oncol 2001;24:10-8.
17. Trudeau ME, Pritchard KI, Chapman JA, Hanna WM, Kahn HJ, Murray D, et al. Prognostic factors affecting the natural history of node-negative breast cancer. Breast Cancer Res Treat 2005;89:35-45.
18. Otsuki Y, Shimizu S, Suwa K, Yoshida M, Kanzaki M, Kobayashi H. Which is the better pathological prognostic factor, the Nottingham histological grade or the Japanese nuclear grade? A large scale study with a long-term follow-up. Jap J Clin Oncol 2007;37:266-74.
19. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006;7:96.
20. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
21. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-74.
22. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-23.
23. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, et al. American Joint Committee on Cancer Staging Manual. 6th edn. Philadelphia: Springer, 2002.
24. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008;14:1368-76.
25. Lin C, Chien SY, Chen LS, Kuo SJ, Chang TW, Chen DR. Triple negative breast carcinoma is a prognostic factor in Taiwanese women. BMC Cancer 2009;9:192.
26. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;98:262-72.
27. Frierson HF, Jr, Wolber RA, Berean KW, Franquemont DW, Gaffey MJ, Boyd JC, et al. Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. Am J Clin Pathol 1995;103:195-8.
28. Robbins P, Pinder S, de Klerk N, Dawkins H, Harvey J, Sterrett G, et al. Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol 1995;26:873-9.
29. Liedtke C, Hatzis C, Symmans WF, Desmedt C, Haibe-Kains B, Valero V, et al. Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol 2009;27:3185-91.
30. Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, Borg A, et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001;61:5979-84.
31. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist 2004;9:606-16.
32. Pohlmann PR, Mayer IA, Mernaugh R. Resistance to trastuzumab in breast cancer. Clin Cancer Res 2009;15:7479-91.
33. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 1993;11:1936-42.
34. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
35. Lovekin C, Ellis IO, Locker A, Robertson JF, Bell J, Nicholson R, et al. c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 1991;63:439-43.
36. Lewis S, Locker A, Todd JH, Bell JA, Nicholson R, Elston CW, et al. Expression of epidermal growth factor receptor in breast carcinoma. J Clin Pathol 1990;43:385-9.
37. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-7.
38. Yin WJ, Lu JS, Di GH, Lin YP, Zhou LH, Liu GY, et al. Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Res Treat 2009;115: 325-33.
39. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22:1736-47.
40. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002;20:3628-36.
41. Contesso G, Jotti GS, Bonadonna G. Tumor grade as a prognostic factor in primary breast cancer. Eur J Cancer Clin Oncol 1989;25:403-9.
42. Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 2006;66:10292-301.